1146 related articles for article (PubMed ID: 10561265)
1. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.
Atkins MB; Lotze MT; Dutcher JP; Fisher RI; Weiss G; Margolin K; Abrams J; Sznol M; Parkinson D; Hawkins M; Paradise C; Kunkel L; Rosenberg SA
J Clin Oncol; 1999 Jul; 17(7):2105-16. PubMed ID: 10561265
[TBL] [Abstract][Full Text] [Related]
2. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.
Fyfe G; Fisher RI; Rosenberg SA; Sznol M; Parkinson DR; Louie AC
J Clin Oncol; 1995 Mar; 13(3):688-96. PubMed ID: 7884429
[TBL] [Abstract][Full Text] [Related]
3. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update.
Atkins MB; Kunkel L; Sznol M; Rosenberg SA
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S11-4. PubMed ID: 10685652
[TBL] [Abstract][Full Text] [Related]
4. Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.
Atkins MB; O'Boyle KR; Sosman JA; Weiss GR; Margolin KA; Ernest ML; Kappler K; Mier JW; Sparano JA; Fisher RI
J Clin Oncol; 1994 Aug; 12(8):1553-60. PubMed ID: 8040667
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
6. Durable complete responses with high-dose bolus interleukin-2 in patients with metastatic melanoma who have experienced progression after biochemotherapy.
Tarhini AA; Kirkwood JM; Gooding WE; Cai C; Agarwala SS
J Clin Oncol; 2007 Sep; 25(25):3802-7. PubMed ID: 17761969
[TBL] [Abstract][Full Text] [Related]
7. Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2.
Lindsey KR; Rosenberg SA; Sherry RM
J Clin Oncol; 2000 May; 18(9):1954-9. PubMed ID: 10784637
[TBL] [Abstract][Full Text] [Related]
8. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.
Legha SS; Ring S; Eton O; Bedikian A; Buzaid AC; Plager C; Papadopoulos N
J Clin Oncol; 1998 May; 16(5):1752-9. PubMed ID: 9586888
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study.
Demchak PA; Mier JW; Robert NJ; O'Brien K; Gould JA; Atkins MB
J Clin Oncol; 1991 Oct; 9(10):1821-30. PubMed ID: 1655988
[TBL] [Abstract][Full Text] [Related]
10. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials.
Flaherty LE; Atkins M; Sosman J; Weiss G; Clark JI; Margolin K; Dutcher J; Gordon MS; Lotze M; Mier J; Sorokin P; Fisher RI; Appel C; Du W
J Clin Oncol; 2001 Jul; 19(13):3194-202. PubMed ID: 11432886
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of "decrescendo" interleukin-2 plus interferon-alpha-2a in patients with progressive metastatic melanoma after chemotherapy.
Eton O; Buzaid AC; Bedikian AY; Smith TM; Papadopoulos NE; Ellerhorst JA; Hibberts JL; Legha SS; Benjamin RS
Cancer; 2000 Apr; 88(7):1703-9. PubMed ID: 10738230
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma.
Atkins MB; Sparano J; Fisher RI; Weiss GR; Margolin KA; Fink KI; Rubinstein L; Louie A; Mier JW; Gucalp R
J Clin Oncol; 1993 Apr; 11(4):661-70. PubMed ID: 8478661
[TBL] [Abstract][Full Text] [Related]
13. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma.
Gibbs P; Iannucci A; Becker M; Allen J; O'Driscoll M; McDowell K; Williams P; Rosse P; Murphy J; Gonzalez R
Melanoma Res; 2000 Apr; 10(2):171-9. PubMed ID: 10803718
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of interleukin-2 administered by continuous infusion in patients with metastatic melanoma.
Legha SS; Gianan MA; Plager C; Eton OE; Papadopoulous NE
Cancer; 1996 Jan; 77(1):89-96. PubMed ID: 8630945
[TBL] [Abstract][Full Text] [Related]
15. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.
Rosenberg SA; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
JAMA; 1994 Mar 23-30; 271(12):907-13. PubMed ID: 8120958
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting.
Hess V; Herrmann R; Veelken H; Schwabe M
Oncology; 2007; 73(1-2):33-40. PubMed ID: 18332650
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of recombinant human interleukin-2 and interferon-alpha-2a: implications for the treatment of patients with metastatic melanoma.
Eton O; Talpaz M; Lee KH; Rothberg JM; Brell JM; Benjamin RS
Cancer; 1996 Mar; 77(5):893-9. PubMed ID: 8608480
[TBL] [Abstract][Full Text] [Related]
18. Sequential dacarbazine chemotherapy followed by recombinant interleukin-2 in metastatic melanoma. A pilot multicentre phase I-II study.
Shiloni E; Pouillart P; Janssens J; Splinter T; Di Peri T; Symann M; Roest GJ; Palmer PA; Franks CR
Eur J Cancer Clin Oncol; 1989; 25 Suppl 3():S45-9. PubMed ID: 2697579
[TBL] [Abstract][Full Text] [Related]
19. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.
Rosenberg SA; Yang JC; White DE; Steinberg SM
Ann Surg; 1998 Sep; 228(3):307-19. PubMed ID: 9742914
[TBL] [Abstract][Full Text] [Related]
20. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
Atkins MB; Gollob JA; Sosman JA; McDermott DF; Tutin L; Sorokin P; Parker RA; Mier JW
Clin Cancer Res; 2002 Oct; 8(10):3075-81. PubMed ID: 12374674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
